MX347981B - Composicion de anticuerpos pan-her. - Google Patents

Composicion de anticuerpos pan-her.

Info

Publication number
MX347981B
MX347981B MX2013004899A MX2013004899A MX347981B MX 347981 B MX347981 B MX 347981B MX 2013004899 A MX2013004899 A MX 2013004899A MX 2013004899 A MX2013004899 A MX 2013004899A MX 347981 B MX347981 B MX 347981B
Authority
MX
Mexico
Prior art keywords
family
pan
antibody compositions
antibody composition
directed
Prior art date
Application number
MX2013004899A
Other languages
English (en)
Other versions
MX2013004899A (es
Inventor
Lantto Johan
Wandahl Pedersen Mikkel
Kragh Michael
Jacobsen Helle
K Christensen Ida
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MX2013004899A publication Critical patent/MX2013004899A/es
Publication of MX347981B publication Critical patent/MX347981B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a las terapéuticas mejoradas contra los receptores dentro de la familia EGFR/ErbB/HER que interfieren más ampliamente con múltiples miembros de la familia HER (inhibición pan-HER). Más particularmente, la invención está dirigida al uso de las composiciones de anticuerpo para la terapia contra el cáncer humano. Los estudios in vitro han mostrado que las composiciones de anticuerpo de la invención que se dirigen a múltiples receptores de la familia HER, son superiores a las composiciones de anticuerpo que se dirigen únicamente a un receptor de la familia HER.
MX2013004899A 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her. MX347981B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40878210P 2010-11-01 2010-11-01
DKPA201000988 2010-11-01
DKPA201100672 2011-09-05
US201161531407P 2011-09-06 2011-09-06
PCT/IB2011/054834 WO2012059857A2 (en) 2010-11-01 2011-10-31 Pan-her antibody composition

Publications (2)

Publication Number Publication Date
MX2013004899A MX2013004899A (es) 2013-07-15
MX347981B true MX347981B (es) 2017-05-22

Family

ID=59014867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004899A MX347981B (es) 2010-11-01 2011-10-31 Composicion de anticuerpos pan-her.
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013004897A MX348637B (es) 2010-11-01 2011-10-31 Anticuerpos y composiciones anti-her3.

Country Status (13)

Country Link
US (1) US9217039B2 (es)
EP (3) EP3156421B1 (es)
JP (2) JP6186277B2 (es)
KR (2) KR101862832B1 (es)
AU (2) AU2011324870B2 (es)
CA (2) CA2816520C (es)
DK (1) DK2635604T3 (es)
ES (2) ES2692379T3 (es)
IL (2) IL225953A0 (es)
MX (2) MX347981B (es)
PL (1) PL2635604T3 (es)
TW (1) TW201231066A (es)
WO (2) WO2012059858A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137874B (zh) * 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
CA2782571C (en) 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition
US20150231238A1 (en) * 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
EP2710038B1 (en) * 2011-05-16 2018-01-17 Yeda Research and Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
CA2838695C (en) * 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX358728B (es) * 2012-05-02 2018-09-03 Symphogen As Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
SI3508502T1 (sl) * 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
JP2017534574A (ja) 2014-09-08 2017-11-24 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
CN114426578B (zh) * 2019-02-14 2025-03-21 美勒斯公司 结合egfr、her2及her3的结合部分的组合
CA3130248A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3.
US20220259290A1 (en) * 2019-07-24 2022-08-18 Japan Science And Technology Agency Innovative production technique for antibody-enzyme
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
TW202413419A (zh) 2022-05-27 2024-04-01 法商賽諾菲公司 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物
EP4713360A1 (en) 2023-05-19 2026-03-25 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126303A (en) 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AUPQ105799A0 (en) * 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
WO2004087763A1 (ja) * 2003-03-31 2004-10-14 Chugai Seiyaku Kabushiki Kaisha Ｃｄ２２に対する改変抗体およびその利用
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
AU2005263334C1 (en) 2004-07-20 2011-01-20 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US20060121044A1 (en) 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
PL2129396T3 (pl) * 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
MX338151B (es) 2007-03-01 2016-04-05 Symphogen As Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico.
PL2152872T3 (pl) 2007-05-25 2011-03-31 Symphogen As Sposób wytwarzania rekombinowanego białka poliklonalnego
NZ584684A (en) 2007-11-22 2012-10-26 Symphogen As A method for characterization of a recombinant polyclonal protein
KR20110016899A (ko) 2008-04-23 2011-02-18 심포젠 에이/에스 폴리클로날 단백질을 제조하는 방법
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
CN102137874B (zh) * 2008-08-29 2015-02-18 西福根有限公司 抗表皮生长因子受体的重组抗体组合物
MX2011003480A (es) * 2008-10-06 2011-04-21 Symphogen As Metodo para identificar y seleccionar candidatos de farmaco para productos de farmacos de combinacion.
NZ594665A (en) * 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
SG177560A1 (en) * 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
SG178509A1 (en) * 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
TW201141519A (en) 2010-03-04 2011-12-01 Symphogen As Anti-HER2 antibodies and compositions
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
PL2606070T3 (pl) * 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition

Also Published As

Publication number Publication date
IL225954B (en) 2018-05-31
EP2635605B1 (en) 2018-07-25
EP3156421A1 (en) 2017-04-19
WO2012059857A2 (en) 2012-05-10
JP2014503188A (ja) 2014-02-13
KR20140026336A (ko) 2014-03-05
EP3156421B1 (en) 2018-06-06
TW201231066A (en) 2012-08-01
AU2011324870A1 (en) 2013-01-31
MX2013004897A (es) 2013-07-15
KR101862832B1 (ko) 2018-05-30
CA2816519C (en) 2019-01-15
DK2635604T3 (en) 2017-02-27
WO2012059857A3 (en) 2012-07-19
ES2692379T3 (es) 2018-12-03
JP6186277B2 (ja) 2017-08-23
EP2635604B1 (en) 2016-11-30
AU2011324871B2 (en) 2016-05-19
WO2012059858A1 (en) 2012-05-10
PL2635604T3 (pl) 2017-09-29
JP2014503189A (ja) 2014-02-13
MX348637B (es) 2017-06-22
AU2011324871A1 (en) 2013-05-09
ES2616961T3 (es) 2017-06-14
KR101773120B1 (ko) 2017-08-30
CA2816520A1 (en) 2012-05-10
IL225953A0 (en) 2013-07-31
MX2013004899A (es) 2013-07-15
KR20140026337A (ko) 2014-03-05
EP2635605A4 (en) 2014-10-22
AU2011324870B2 (en) 2015-01-29
US9217039B2 (en) 2015-12-22
EP2635605A1 (en) 2013-09-11
JP6033783B2 (ja) 2016-11-30
CA2816520C (en) 2017-11-21
EP2635604A2 (en) 2013-09-11
IL225954A0 (en) 2013-07-31
CA2816519A1 (en) 2012-05-10
US20130287684A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
MX347981B (es) Composicion de anticuerpos pan-her.
PH12012501993A1 (en) Pyrazolyl quinazoline kinase ihibitors
NZ604003A (en) Monoclonal antibodies against her2
IN2012DN02081A (es)
NZ626610A (en) Antibodies that bind csf1r
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
TN2012000462A1 (en) Anti-cd40 antibodies
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
PH12013500955A1 (en) Spiro-oxindole mdm2 antagonists
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
EA020330B3 (ru) Хиназолиновые соединения
PH12013500648A1 (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
NZ602992A (en) Prophylaxis of colorectal and gastrointestinal cancer
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
EA201101180A1 (ru) Производные триазоло[4,3-в]пиридазина и их применение для рака предстательной железы
PH12012502102A1 (en) Fused bicyclic kinase inhibitors
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
NZ757754A (en) Antibodies that bind csf1r
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия

Legal Events

Date Code Title Description
FG Grant or registration